Commercial success does not end with a successful launch. Lifecycle management determines whether products realize their full value potential or lose relevance prematurely.
Why this area is critical
In the life science industry, lifecycle management is not a downstream optimization step, but a strategic steering process that integrates medical, regulatory and commercial decisions over many years.
Company perspective
For companies, lifecycle management means:
- Active value steering across the entire product lifecycle
- Prioritization of indication extensions, subpopulations or new formulations
- Adaptation of positioning, pricing and go to market strategies to changing market conditions
- Timely preparation for competitive dynamics, generics or biosimilars
Without a clear lifecycle strategy, value is often exploited reactively rather than strategically.
Investor perspective
For investors, lifecycle management is a central value driver:
- How sustainable is the revenue and margin potential?
- Is there a clear logic for value creation over time?
- How well is the company prepared for competitive and pricing pressure?
Lack of lifecycle management significantly increases the risk of early value erosion.
Typical risks and misjudgements
In practice, we frequently observe:
- Lifecycle strategies developed only after launch
- Unclear prioritization of development and investment options
- Insufficient alignment between clinical development and commercial strategy
- Inadequate preparation for competition or patent expiry scenarios
- Inefficient allocation of resources across products and indications
These risks rarely arise from a lack of ideas, but from missing structure and decision logic.
What Excellere delivers in practice
Excellere supports companies and investors in establishing lifecycle management in a structured, realistic and value oriented manner. Our services include, among others:
- Development of integrated lifecycle s trategies across clinical, regulatory and commercial dimensions
- Evaluation of indication extensions and new target populations based on clear value drivers
- Adjustment of positioning, pricing and go to market logics throughout the lifecycle
- Preparation from competition, generics or biosimilar scenarios
- Derivation of clear roadmaps and decision gates for management
The objective is to systematically secure and further develop value over time.
Integration of development, market and organization
Our work in lifecycle management is deliberately integrated. We assess lifecycle decisions in the interplay of:
- Clinical evidence and development options
- Regulatory framework conditions
- Market, pricing and market access logics
- Organizational feasibility and resource availability
This ensures that lifecycle strategies are not planned in isolation, but can be implemented consistently.
Added value for companies and investors
For companies
- Clear prioritization of development and investment decisions
- Better utilization of existing product potential
- Higher efficiency in resource allocation
- Structured preparation for market changes
For investors
- Increased transparency regarding long term value drivers
- Improved assessment of sustainability and risk
- More stable revenue and margin perspectives
- Reduced dependence on short term growth effects
How we work
Lifecycle management project at Excellere are led by senior management and, depending on product, indication or market, complemented by our consultant and partner network. We work:
- Strategically and decision oriented
- Integrated with clinical, commercial and organizational functions
- Grounded in operational reality rather than theory
- Without delegation to junior teams
Our ambition is to establish lifecycle management as an active value lever, not as a reactive measure.
When long term value needs to be secured
Sustainable success does not result from one off decisions, but from consistent steering across the entire lifecycle. Let us jointly assess how Excellere can be support you in securing and further developing product value over the long term.



-6.jpg/picture-200?_=197ceb5dad0)